针对代谢状态的最佳医学疗法用于皮肤冠状动脉干预的患者的二次预防
Imma Forzano1, Viviana Narciso1, Mario Enrico Canonico1,2
1Department of Advanced Biomedical Sciences, Federico II University of Naples, 80131 Naples, Italy.
Journal of clinical medicine
|February 13, 2026
概括
心血管疾病是全球主要的健康问题. 本综述探讨了针对肥胖和糖尿病的新药策略,以减少穿皮冠状动脉干预后患者的残留心血管风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 心血管疾病,特别是由于动脉样硬化导致的冠状动脉疾病 (CAD),是全球死亡的主要原因.
- 动脉硬性斑块会导致慢性或急性冠状动脉综合征,而接受皮肤冠状动脉干预 (PCI) 的患者面临非常高的心血管风险.
- 尽管目前正在进行治疗,但这些患者仍然存在残留性缺血风险,这凸显了加强二次预防的必要性.
研究的目的:
- 审查针对二次心血管预防的代谢途径的药理学策略.
- 专注于通过皮肤进行冠状动脉干预后患者的肥胖和糖尿病干预措施.
主要方法:
- 对新出现的证据进行叙述性审查.
- 检查针对脂质代谢,炎症和代谢功能障碍的药理学策略.
- 在二次预防的背景下分析肥胖和糖尿病的治疗方法.
主要成果:
- 目前的二次预防解决了可修改的风险因素,但留下了显著的剩余风险.
- 脂质代谢,炎症和代谢功能障碍是残留风险的关键因素.
- 对肥胖和糖尿病的药理学向显示出改善结果的希望.
结论:
- 在高风险患者中,存在大量未满足的治疗需求,以减少残留心血管风险.
- 针对代谢途径,特别是肥胖和糖尿病,为新的二次预防策略提供了一个有希望的途径.
- 对这些药理方法的进一步研究对于改善皮肤冠状动脉干预后患者的治疗结果至关重要.
关键词:
急性冠状动脉综合征 (ACS) 是一种疾病.慢性冠状动脉综合征 (CCS) 是一种慢性冠状动脉综合征.冠状动脉疾病 (CAD) 是一种冠状动脉疾病.糖尿病 糖尿病患者 糖尿病患者代谢状态 代谢状态肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖通过皮肤进行冠状动脉干预 (PCI)二次预防二次预防.更多相关视频
10:21Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
Published on: September 22, 2023
1.0K
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
6.0K
相关概念视频
01:26Coronary Artery Disease IV: Preventive Measures
735
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
735
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
451
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
451
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
247
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
247
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
227
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
227
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197